Two novel series of oxazepine and diazepine based HSP90 inhibitors are reported. This effort relied on structure based design and isothermal calorimetry to identify small drug like macrocycles. Computational modelling was used to build into a solvent exposed pocket near the opening of the ATP binding site, which led to potent inhibitors of HSP90 (25-30). (C) 2015 Elsevier Ltd. All rights reserved.
[EN] SULFONAMIDES DERIVATIVES AS URAT1 INHIBITORS<br/>[FR] DÉRIVÉS SULFONAMIDES UTILISÉS EN TANT QU'INHIBITEURS D'URAT1
申请人:PFIZER LTD
公开号:WO2016034971A1
公开(公告)日:2016-03-10
The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a sulfonamide URAT1inhibitor of formula (I), or a pharmaceutically acceptable salt thereof for use as a medicament, wherein R1, X1 and m as defined in the description, and to certain new sulfonamide URAT1 inhibitors. URAT1 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly gout.
The reaction of methyl 2-chloro-5-ethoxycarbonylamino-4-fluorobenzoate (4a) and 1-bromo-3, 3-dimethyl-2-butanone (2) in the presence of 2.2 eq of lithium bis(trimethylsilyl)amide afforded the 4H-1, 4-benzoxazine (6a) in good yield instead of the expected 4-oxazolin-2-one (5a). The generality of the reaction and the mechanism are discussed.